| Literature DB >> 31632982 |
Havva Yalinca1, Charlotte Julie Caroline Gehin2, Vladimiras Oleinikovas1, Hilal A Lashuel2, Francesco Luigi Gervasio1,3, Annalisa Pastore4.
Abstract
Huntington disease is a neurodegenerative disease characterized by a polymorphic tract of polyglutamine repeats in exon 1 of the huntingtin protein, which is thought to be responsible for protein aggregation and neuronal death. The polyglutamine tract is preceded by a 17-residue sequence that is intrinsically disordered. This region is subject to phosphorylation, acetylation and other post-translational modifications in vivo, which modulate its secondary structure, aggregation and, subcellular localization. We used Molecular Dynamics simulations with a novel Hamiltonian-replica-exchange-based enhanced sampling method, SWISH, and an optimal combination of water and protein force fields to study the effects of phosphorylation and acetylation as well as cross-talk between these modifications on the huntingtin N-terminus. The simulations, validated by circular dichroism, were used to formulate a mechanism by which the modifications influence helical conformations. Our findings have implications for understanding the structural basis underlying the effect of PTMs in the aggregation and cellular properties of huntingtin.Entities:
Keywords: Huntington's disease; enhanced sampling; misfolding disease; molecular dynamics; peptide folding; phosphorylation; post-translational modifications
Year: 2019 PMID: 31632982 PMCID: PMC6779701 DOI: 10.3389/fmolb.2019.00095
Source DB: PubMed Journal: Front Mol Biosci ISSN: 2296-889X
Figure 1Cartoon representation of the starting structure (PDB ID: 2LD0) (A), replica with lowest lambda value (λ = 0.85) in the WT peptide (B), and that with the highest lambda value (λ = 1.10) (C). The N and C termini are shown as blue and red spheres, respectively.
Experimental and simulation-derived helical content of the Htt1-19 peptides.
| WT | MATLEKLMKAFESLKSFQQ | 6.8 | 8 |
| pThr3 | MA | 11.9 | 15 |
| pThr3, pSer13 | MA | 8.2 | 8 |
| pThr3, pSer16 | MA | 9.7 | 9 |
| pThr3, pSer13, pSer16 | MA | 8.5 | 7 |
| pSer16 | MATLEKLMKAFESLK | 7.5 | 7 |
| pThr3, acLys6 | MA | 6.8 | n.d. |
| acLys6 | MATLE | 12.7 | n.d. |
| pThr3, acMet1 | 14.6 | 25 | |
| acMet1 | 7.0 | 7 | |
| ac2-17 WT | n.d. | 0.5 | |
| ac2-17acLys6 | n.d. | 9 |
The modified residues are shown in bold. The indications ac and p stand for acetylation and phosphorylation, respectively. Met1 and Ala2 acetylation is at the N-terminus, while that of Lys6 is on the side chain.
Figure 2Helicity per residue for the simulated peptides is shown as a stacked bar plot. The helix percentage (divided into α and 310 helix) was evaluated according to DSSP.
Figure 3Frequency of backbone hydrogen bond formation. The hydrogen bonds between the carbonyl of each residue (labeled in the 1st row) with the amide proton of each of the following four residues (rows) are shown.